Navigating Treatment Options for Giant Cell Arteritis

This chapter discusses a pivotal study of 430 patients with Giant Cell Arteritis, focusing on the safety risks of treatments like upadacitinib compared to tocilizumab. The conversation emphasizes the challenges in patient enrollment and the need for a tailored approach to therapy, anticipating a future with more diverse treatment options.